Prothena Corporation plc develops investigational therapeutics built on protein dysregulation expertise for neurodegenerative and rare peripheral amyloid diseases. Company news commonly covers clinical and partner updates for programs such as prasinezumab in Parkinson’s disease, coramitug in ATTR amyloidosis with cardiomyopathy, BMS-986446 in Alzheimer’s disease, PRX019, and CYTOPE-based research.
Updates also include financial results, cash guidance, collaboration revenue and milestone payments from strategic partners, regulatory designations, share repurchase activity, shareholder capital actions, and leadership or governance changes.
Prothena plc (NASDAQ:PRTA) will report its first quarter 2024 financial results on May 8, 2024, after the close of the U.S. financial markets. The company, a late-stage clinical biotechnology firm focusing on investigational therapeutics, will not host a conference call along with the results release.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.